CEO
Richard Fair
Employees
13
Industry
Pharmaceutical Preparation Manufacturing
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company's next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum's GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.
Loading...
Open
0.08
Mkt cap
778K
Volume
6.1K
High
0.09
P/E Ratio
-0.11
52-wk high
1.31
Low
0.07
Div yield
N/A
52-wk low
0.06
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.